165126-71-6

Basic information

• Product Name: 1-Propanone,1-(6-methyl-2-pyridinyl)-(9CI)
• Synonyms: 1-Propanone,1-(6-methyl-2-pyridinyl)-(9CI);1-(6-Methylpyridin-2-yl)propan-1-one
• CAS NO: 165126-71-6
• Molecular Formula: C9H11NO
• Molecular Weight: 149.19
• Product Categories: PYRIDINE
• Mol File: 165126-71-6.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-Propanone,1-(6-methyl-2-pyridinyl)-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Propanone,1-(6-methyl-2-pyridinyl)-(9CI)(165126-71-6)
• EPA Substance Registry System: 1-Propanone,1-(6-methyl-2-pyridinyl)-(9CI)(165126-71-6)

Safety Data

• Hazardous Substances Data: 165126-71-6(Hazardous Substances Data)

Upstream product

• 1620-75-3 2-Cyano-6-methylpyridine 
• 925-90-6 ethylmagnesium bromide 
• 81684-02-8 1-(6-methylpyridin-2-yl)propan-1-ol 

Relevant articles and documents

ADENOSINE RECEPTOR BINDING COMPOUNDS

The present invention relates to pharmaceutical compounds and compositions of Formula (I) and methods of treatment using the compounds and compositions, especially for the treatment and/or prevention of a proliferation disorder, such as cancer. Compounds of Formula (I) as further described herein are shown modulators of the adenosine A2A receptor and exhibit antiproliferative activity. Accordingly, these compounds are useful to treat proliferative disorders such as cancer, and other adenosine receptor-related conditions including an inflammatory disease, renal disease, diabetes, vascular disease, lung disease, or an autoimmune disease.

ALKYL SULFONAMIDE DERIVATIVES

This invention is directed to alkyl sulfonamide derivatives which are ligands at the NPY Y5 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by admixing a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression which comprises administering to the subject an amount of a compound of the subject invention. This invention also provides a method of treating a subject suffering from anxiety which comprises administering to the subject an amount of a compound of the subject invention. This invention also provides a method of treating a subject suffering from obesity which comprises administering to the subject an amount of a compound of the subject invention.

New Alkaloids from Ants: Identification and Synthesis of (3R,5S,9R)-3-Butyl-5-(1-oxopropyl)indolizidine and (3R,5R,9R)-3-Butyl-5-(1-oxopropyl)indolizidine Constituents of the Poison Gland Secretion in Myrmicaria eumenoides (Hymenoptera Formicidae)

The (3R,5S,9R) and (3R,5R,9R) stereoisomers of 3-butyl-5-(1-oxopropyl)indolizidine (9) were identified as major constituents of the poison gland secretion of the African ant, Myrmicaria eumenoides.Racemates of the four diastereomers of 9 were synthesized via the corresponding ethyl 5-(5-butylpyrrolidin-2-yl)pentanoates (6).Enantiomerically pure samples of the (3R)-stereoisomers of 9 were obtained by starting from (2R)-2,3-O-isopropylideneglyceric aldehyde (21) and 6-methylpyridine-2-carboxaldehyde (20).In addition, the enantiomeric separation by chiral gas chromatography and unambiguous structure assignment of the target compounds are described. - Key Words: Ants/ Alkaloids/ Myrmicaria eumenoides/ 3-Butyl-5-(1-oxopropyl)indolizidine, (3R,5S,9R)-, (3R,5R,9R)-